There is strong global interest in the work of biotech companies and next week's Proactive Biotech Webinar will feature a number of ASX-listed companies making strong progress in the field.
Each company will present for 12 minutes, followed by a 5-minute Q&A session.
The webinar will also be live-streamed on the Proactive YouTube channel, which can then be viewed at any time following the presentation.
Discussing operational highlights
Company executives will outline recent operational highlights and upcoming plans.
Pharmaxis chief executive officer Gary Phillips (below) will outline the Australian pharmaceutical company's expertise in developing drugs for inflammatory and fibrotic diseases.
The company has this week reached the top biotech echelon with the US Food & Drug Administration (FDA) agency’s approval of its cystic fibrosis treatment Bronchitol® (mannitol) representing a transformational milestone.
Not many Australian companies can boast the gold standard of success in biotech – US FDA approval of a medicine it has researched and developed – with CEO Phillips saying this was a “transformational step”.
Cynata managing director Dr Ross Macdonald (below) plans to highlight the company's progress towards multiple clinical trials using its Cymerus™ mesenchymal stem cell (MSC) products.
Recce Pharmaceuticals chief executive officer James Graham (below) will summarise the company’s operational highlights for the September quarter and its pathway towards developing and commercialising a new class of Synthetic Anti-infectives.